Clinical Trial Update: A Study to Investigate the Efficacy and Safety of GSK1605786A in the Treatment of Subjects With Moderately-to-Severely Active Crohn's Disease [Phase 3]

View source ↗

Summary

Phase 3 trial completed for GSK1605786A in moderately-to-severely active Crohn's disease; results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Crohn Disease

Drugs mentioned

• GSK1605786A

Snippet

Sponsor: GlaxoSmithKline | Conditions: Crohn's Disease | Phase 3 | Status: COMPLETED | Results posted: 2017-09-19